Wall Street just received a clear message from the October jobs report. The economy is still running hot, the Federal Reserve may stay tough on rates, and investors are again asking what truly holds up when borrowing costs stay elevated. That is where defensive, dividend-paying US healthcare stocks earn a closer look. This article explains the backdrop and then outlines three stocks connected to this news that some investors may want on their watchlist.
The three defensive, dividend-paying US healthcare stocks in this article are just a sample of the idea, and the full screen surfaced 7 more companies with equally grounded payout profiles and business stories that are not covered here. To see the wider field, head straight to the Defensive, Dividend-Paying US Healthcare Stocks screener to identify, filter, and analyze the highest-conviction candidates that fit these criteria.
Royalty Pharma (RPRX)
Overview:Royalty Pharma acquires biopharmaceutical royalties and funds drug development, collecting payments on a diversified portfolio of marketed and pipeline therapies.
Operations:Royalty Pharma generates US$2.6b in revenue from acquiring biopharmaceutical royalties, with all receipts currently sourced from the United States.
Market Cap:US$38.6b
Royalty Pharma fits this defensive, dividend-paying healthcare screen because its royalty-focused model converts drug sales across many therapies into diversified cash flows that can help support regular distributions even when markets are unsettled.
"The company is investing heavily in AI on top of a long built data platform, including hiring the former Head of AI at IQVIA and assembling decades of patient level and clinical trial data into trained models. Management expects this to first improve diligence depth and speed and then become a value added tool for partners. This may give Royalty Pharma a differentiated way to win future royalty mandates and support revenue and margin resilience.
What happens if one key assumption about how effectively those royalties offset higher funding costs and pricing pressure shifts over time?
If that assumption matters to your thesis, read the full narrative for Royalty Pharma to see how Royalty Pharma's cash engine could decouple from funding and pricing pressure.
Gilead Sciences (GILD)
Overview:Gilead Sciences develops and sells antiviral and oncology medicines, with HIV and liver disease treatments forming the core of its dividend-focused, defensive profile.
Operations:Gilead Sciences generates US$31.0b in revenue from discovering, developing and commercializing medicines, with around US$22.8b coming from the United States and the balance from Europe and the rest of the world.
Market Cap:US$207.0b
Gilead Sciences matters for a defensive, dividend-paying healthcare screen because its long-running HIV franchise and cash generative antiviral portfolio support a regular payout even when rates stay higher for longer.
"Transition to long-acting therapies (lenacapavir) is a key growth driver for HIV, as the shift from daily oral to long-acting injectable PrEP could expand the TAM. Near-term EPS compression from acquisitions (2026 loss expected) and integration risk remain material execution risks."
What investors really need to watch is how one pressure point on future cash generation shapes the balance between income and reinvestment.
That trade off sits at the heart of Gilead Sciences right now, and the full narrative for Gilead Sciences shows how that tension could evolve into an accelerating income story.
Stryker (SYK)
Overview:Stryker Corporation supplies medical technology ranging from surgical tools and neurotech systems to orthopedic implants such as hips, knees and shoulders.
Operations:Stryker generates about US$9.9b from Orthopaedics and US$16.4b from MedSurg and Neurotechnology, anchored by a large U.S. customer base.
Market Cap:US$124.1b
Stryker matters for this defensive, dividend-paying healthcare screen because its essential surgical and orthopedic gear tends to see relatively steady procedure demand, which can support predictable earnings and an income stream when higher rates pressure more cyclical sectors.
"Expanding use of Stryker's Mako platform, including record installations, broader procedure coverage such as shoulder and advanced hip or revision, and the rollout of Mako RPS for handheld knee robotics, may support a larger orthopedic addressable market and could influence revenue and associated service earnings over time."
The key consideration is how one lingering operational and legal overhang ultimately affects margins as that robotics strategy develops.
That margin question is exactly where the story gets interesting, and the full narrative for Stryker unpacks how Stryker's robotics push could either accelerate earnings power or mask brewing risks.
Seeking Alternatives Before The Crowd?
Fresh ideas move first. Breakout themes gain momentum while slower money gets caught reacting late, once prices are already flying. Scan new angles that are under the radar for now and consider acting before conditions change.
-
Spot potential trend leaders early by reviewing the 19 high quality undiscovered gems before attention increases and the most interesting opportunities stop looking cheap.
-
Target resilient income payers by running through the 7 dividend fortresses while yields remain elevated and quality cash flows may still be mispriced.
-
Consider possible energy shifts by assessing infrastructure players in the 17 nuclear energy infrastructure stocks while sentiment is still adjusting to the underlying buildout.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
